<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Bone and soft tissue sarcomas, tumors of the skin</journal-id><journal-title-group><journal-title xml:lang="en">Bone and soft tissue sarcomas, tumors of the skin</journal-title><trans-title-group xml:lang="ru"><trans-title>Саркомы костей, мягких тканей и опухоли кожи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4614</issn><issn publication-format="electronic">2782-3687</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SOFT TISSUE SARCOMAS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>САРКОМЫ МЯГКИХ ТКАНЕЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modern views on the perfusion chemotherapy possibilities in the malignant tumors treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Современные представления о возможностях применения перфузионной химиотерапии в лечении злокачественных опухолей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kharatishvili</surname><given-names>T. K.</given-names></name><name xml:lang="ru"><surname>Харатишвили</surname><given-names>Т. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Petrochenko</surname><given-names>N. S.</given-names></name><name xml:lang="ru"><surname>Петроченко</surname><given-names>Н. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>petrochenko_nikolayy@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Burov</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Буров</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bohyan</surname><given-names>B. Yu.</given-names></name><name xml:lang="ru"><surname>Бохян</surname><given-names>Б. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kumekhov</surname><given-names>Z. Yu.</given-names></name><name xml:lang="ru"><surname>Кумехов</surname><given-names>З. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sipratova</surname><given-names>K. V.</given-names></name><name xml:lang="ru"><surname>Сипратова</surname><given-names>К. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kiva</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Кива</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">FGBU DPO Russian medical academy continuous professional education of the Ministry of health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ ДПО Российская медицинская академия непрерывного профессионального образования Министерства здравоохранения Российской Федерации</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University (RNRMU)</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-05-16" publication-format="electronic"><day>16</day><month>05</month><year>2019</year></pub-date><volume>11</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>18</fpage><lpage>24</lpage><history><date date-type="received" iso-8601-date="2021-04-16"><day>16</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Kharatishvili T.K., Petrochenko N.S., Burov D.A., Bohyan B.Y., Kumekhov Z.Y., Sipratova K.V., Kiva E.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Харатишвили Т.К., Петроченко Н.С., Буров Д.А., Бохян Б.Ю., Кумехов З.Ю., Сипратова К.В., Кива Е.В.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Kharatishvili T.K., Petrochenko N.S., Burov D.A., Bohyan B.Y., Kumekhov Z.Y., Sipratova K.V., Kiva E.V.</copyright-holder><copyright-holder xml:lang="ru">Харатишвили Т.К., Петроченко Н.С., Буров Д.А., Бохян Б.Ю., Кумехов З.Ю., Сипратова К.В., Кива Е.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://sarbon.abvpress.ru/jour/article/view/67">https://sarbon.abvpress.ru/jour/article/view/67</self-uri><abstract xml:lang="en"><p>Currently, the complex treatment of malignant neoplasms of various localizations is used perfusion technology more commonly. We performed the analysis of literature on the use of perfusion chemotherapy in the treatment of tumors. The basic physical principles of delivering a chemotherapy drug (CP) to tumor tissues were considered, and it was noted that to ensure the effectiveness of this process, it is necessary to overcome high vascular resistance, high pressure of interstitial fluid and fibrous stroma around the tumor. It presented the factors contributing to the increase in CP in interstitial tissue, including ischemic vasodilation, low viscosity of injected fluids and bolus drug delivery. It is noted that when applying the method of intraarterial perfusion, the pressure of fluid flow increases, this causes the «leaching» of the intravascular protein in the interstitium, CP does not undergo reabsorption in the venous section, and the tumor is completely retained by the tissue. It is indicated that further study of the physicochemical principles of the application of this method will contribute to a significant increase in the survival rate of cancer patients in whom conservative treatment methods prove ineffective.</p></abstract><trans-abstract xml:lang="ru"><p>В настоящее время при комплексном лечении злокачественных новообразований различных локализаций все шире применяются перфузионные технологии. Выполнен анализ литературных данных о применении перфузионной химиотерапии в лечении опухолей. Рассмотрены базовые физические принципы доставки химиопрепарата (ХП) в опухолевые ткани, при этом отмечено, что для обеспечения эффективности этого процесса необходимо преодолеть высокое сосудистое сопротивление, высокое давление интерстициальной жидкости и фиброзной стромы вокруг опухоли. Представлены факторы, способствующие увеличению поступления ХП в интерстициальную ткань, в том числе ишемическая вазодилатация, незначительная вязкость вводимых жидкостей и болюсная доставка препарата. Отмечено, что при применении метода внутриартериальной перфузии увеличивается давление притока жидкости, при этом происходит «вымывание» внутрисосудистого белка в интерстиций, ХП не подвергается реабсорбции в венозном отделе, достигается полное удержание препарата тканью опухоли. Указано, что дальнейшее изучение физико-химических основ применения этого метода будет способствовать существенному повышению выживаемости онкологических пациентов, у которых консервативные методы лечения оказываются малоэффективными.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chemotherapy</kwd><kwd>malignant tumors</kwd><kwd>intraarterial perfusion</kwd><kwd>fluid mass transfer (MFT)</kwd><kwd>oncotic pressure</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>химиопрепарат</kwd><kwd>злокачественные опухоли</kwd><kwd>интраартериальная перфузия</kwd><kwd>массопередача жидкости (MFT)</kwd><kwd>онкотическое давление</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kemeny GA, Kanat NO. What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentarium against colorectal cancer. J Gastrointest Oncol. 2012;3:130-138. DOI: 10.3978/j.issn.2078-6891.2011.025.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Interv Radiol. 2016;39:801-804. https://doi. org/10.1007/s00270-015-1276-z.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lane RJ, Khin NY, Rogan CM, Magnussen JS, Ho-Shon KB, Pavlakis NF, Clarke SJ, Hugh TJ. The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. J Control Release. 2018;28(292):18-28. DOI: 10.1016/j.jconrel.2018.10.019.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Rofstad EK, Galappathi K, Mathiesen BS. Tumor interstitial fluid pressure - a link between tumor hypoxia, microvascular density, and lymph node metastasis. Neoplasia. 2014;16:586-594. https://doi.org/10.1016/j.neo.2014.07.003.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Stapleton S, Milosevic M, Allen C, Zheng J, Dunne M, Yeung I, Jaffray DA. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLoS One. 2013;8(12):e81157. DOI: 10.1371/ journal.pone.0081157.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Fisher DT, Muhitch JB, Kim M, Doyen KC, Bogner PN, Evans SS, Skitzki JJ. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun. 2016;7:10684. https://doi.org/10.1038/ncomms10684.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Van der Veldt AA, Lubberink M, Mathijssen RHJ, Loos WJ, Herder GJ, Greuter HN et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [(1)(1)C]docetaxel and positron emission tomography. Clin Cancer Res. 2013;19:4163-4173. https://doi. org/10.1158/1078-0432.CCR-12-3779.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Pingpank JE, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465-3474. https://doi.org/10.1200/ JCO.2005.00.927.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo. 2014;186:937-944. https://doi. org/10.1055/s-0034-1366081.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lane RJ, Khin NY, Rogan CM, Magnussen J, Pavlakis N, Lane DM, Clarke S. Safety and feasibility of repeatable hepatic vascular isolation chemotherapy: a pilot study. Ann Surg Oncol. 2016;23:3699-3708. https://doi.org/10.1245/ s10434016-5198-z.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Devic S. Warburg effect - aconsequence or the cause of carcinogenesis? J Cancer. 2016;7:817-822. https://doi. org/10.7150/jca.14274.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Khin NY, Dijkstra ML, Huckson M, Phillips M, McMillan D, Itoh S et al. Hypertensive extracorporeal limb perfusion for critical limb ischemia. J Vasc Surg. 2013;58:1244-1253. https://doi.org/10.1016/j.jvs.2013.05.004.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Agarwala SS, Eggermont AM, O’Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014;120:781-789. https://doi.org/10.1002/cncr.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108:384-394. https:// doi: 10.1093/bja/ aer515.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Taurin S, Nehoff H, van Aswegen T, Greish K. Tumor vasculature, EPR effect, and anticancer nanomedicine: connecting the dots. In: Y.H. Bae, R.J. Mrsny, K. Park (eds.), Cancer Target. Drug Deliv. - An Elus, Dream, Springer New York, New York, NY 2013:207-239. https://doi.org/10.1007/978-1-4614-7876-8-8.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther. 2007;82:252-264. https://doi. org/10.1038/sj.clpt.6100301.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683-692. https:// doi.org/10.1089/scd.2008.0253.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Pendharkar AV, Chua JY, Andres RH, Wang N, Gaeta X, Wang A et al. Biodistribution of neural stem cells after intravascular therapy for Hypoxic-ischemia. Stroke. 2010;41:2064-2070. https://doi.org/10.1161/STROKEAHA.109.575993.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Clavreul A, Pourbaghi-Masouleh M, Roger E, Lautram N, Montero-Menei CN, Menei P. Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal? J Exp Clin Cancer Res. 2017;36:135. https://doi. org/10.1186/s13046-017-0605-2.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Liu X, Yang X, Zhou G, Chen Y, Li C, Wang X. Gemcit-abine-based regional intraarterial infusion chemotherapy in patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore). 2016;95:e3098. https://doi.org/10.1097/ MD.0000000000003098.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Fiorentini G, Tsetis D, Varveris C, Montagnani F, Kalogeraki A, Mambrini A et al. Induction intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer. In: K.R. Aigner, F.O. Stephens (eds.), Induction Chemother, Springer Berlin Heidelberg, Berlin, Heidelberg. 2011:139-149. https://doi.org/10.1007/9783-642-18173-3-10.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Secomb TW, Konerding MA, West CA, Su M, Young AM, Mentzer SJ. Microangiectasias: structural regulators of lymphocyte transmigration. Proc Natl Acad Sci U.S.A. 2003;100:7231-7234. https://doi.org/10.1073/pnas. 1232173100.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Sleeman J, Schmid A, Thiele W Tumor lymphatics. Semin Cancer Biol. 2009;19:285-297. https://doi.org/10.1016/j. semcancer.2009.05.005.</mixed-citation></ref></ref-list></back></article>
